Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04098445 · ClinicalTrials.gov registry record
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
A clinical trial of Bronchiolitis Obliterans and Hematopoietic Stem Cell Transplant (HSCT), sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 9
- Study locations
NCT04098445: Recruiting study of Bronchiolitis Obliterans and Hematopoietic Stem Cell Transplant (HSCT), sponsored by Children's Hospital Medical Center, Cincinnati.
NCT04098445 is a study of Bronchiolitis Obliterans and Hematopoietic Stem Cell Transplant (HSCT) that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 2,000 participants, above the 187-participant average among 9 other Bronchiolitis Obliterans trials with a reported enrollment target (970% higher). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04098445, a study of Bronchiolitis Obliterans and Hematopoietic Stem Cell Transplant (HSCT), is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 9
- Study locations
Study Summary
Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary morbidity affects as many as 25% of children receiving transplant. Early pulmonary injury includes diffuse alveolar hemorrhage (DAH), thrombotic microangiopathy (TMA) interstitial pneumonitis (IPS) and infection, while later, bronchiolitis obliterans is a complication of chronic GVHD associated with severe morbidity and mortality. Improved diagnosis and treatment of pulmonary complications are urgently needed as survival after HSCT improves, and as HSCT is increasingly used for non-malignant disorders such as sickle cell disease. Currently, there are large and important gaps in the investigator's knowledge regarding incidence, etiology and optimal treatment of pulmonary complications. Moreover, young children unable to perform spirometry are often diagnosed late, and strategies for monitoring therapeutic response are limited. This is a prospective multi-institutional cohort study in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). Assembly of a large prospective uniformly screened cohort of children receiving HSCT, together with collection of biological samples, will be an effective strategy to identify mechanisms of lung injury, test novel diagnostic strategies for earlier diagnosis, and novel treatments to reduce morbidity and mortality from lung injury after transplant.
Primary Outcome
Participants will be assessed for lung injury at 24 months after HSCT
Conditions Studied
Study Locations (9)
Washington
- Seattle Children'S Hospital - Seattle
- Fred Hutchinson Cancer Center - Seattle
California
- University of California San Francisco - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
Massachusetts
- Dana-Farber Cancer Institute/Boston Children's Hospital - Boston
Minnesota
- University of Minnesota - Minneapolis
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- Baylor College of Medicine/Texas Children'S Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2021-09-08 |
| Est. Completion | 2036-09 |
What NCT04098445 shows while recruiting
NCT04098445 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 187-participant average among 9 other Bronchiolitis Obliterans trials with a reported enrollment target (970% higher).
The record links to 5 conditions, with Bronchiolitis Obliterans appearing as the primary indexed condition, and to 0 interventions.
NCT04098445 lists 9 locations in 8 states (Washington, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT04098445 about?
NCT04098445 is a clinical study titled "TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients". Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary morbidity affects as many as 25% of children receiving transplant. Early pulmonary injury includes diffuse alveolar hemorrhage (DAH), thrombotic microangiopathy (TMA) interstitial pneumonitis (IPS) and infectio...
What is the current status of trial NCT04098445?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2021-09-08. Estimated completion is 2036-09.
What conditions does trial NCT04098445 study?
This clinical trial studies the following conditions: Bronchiolitis Obliterans, Hematopoietic Stem Cell Transplant (HSCT), Thrombotic Microangiopathies, Diffuse Alveolar Hemorrhage, Interstitial Pneumonitis.
Who is sponsoring clinical trial NCT04098445?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04098445 being conducted?
This trial has 9 study locations across California, Colorado, Massachusetts, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchiolitis Obliterans
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04098445's enrollment target sits among peer trials
2,000 1st of 9 higher than 9 of 9 other Bronchiolitis Obliterans trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bronchiolitis Obliterans trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome
RECRUITING
-
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
COMPLETED · Phase 3
-
Hp129 Xenon Imaging and BOS in Lung Transplantation
COMPLETED · Phase 1
-
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI